First treatment for Fibromyalgia pain now available in Canada

[Adminஐﻬ]

First treatment for Fibromyalgia pain now available in Canada

   
May 13, 2009

 Pfizer Canada Inc. announced today that LYRICA(R) (pregabalin) is now indicated for the management of pain associated
with fibromyalgia, giving the approximately one million Canadians who suffer from this debilitating condition a key component towards managing their disease.

    This new indication announcement, made on International Fibromyalgia Awareness Day, represents positive news for fibromyalgia sufferers since pain associated with the condition previously had no approved treatment options in Canada.

    Characterized by a chronic widespread pain that can be relentless,fibromyalgia is usually accompanied by poor sleep, stiffness and fatigue;
sufferers also report experiencing deep tenderness, soreness and flu-like aching. There is not one specific cause of fibromyalgia. Some of the
associations that have been identified include heredity, physical trauma, emotional trauma, infection or autoimmune disorders such as rheumatoid
arthritis or lupus.
   
   
    About Pfizer Canada Inc.

    Pfizer Canada Inc. is the Canadian operation of Pfizer Inc, the world's leading pharmaceutical company. Pfizer discovers, develops, manufactures and markets prescription medicines for humans and animals. Pfizer's ongoing research and development activities focus on a wide range of therapeutic areas following our guiding aspiration: Working for a healthier world. For more information, visit www.pfizer.ca.
    LYRICA is a trade-mark of Pfizer Products Inc., Pfizer Canada Inc., licensee.